 |
Martin Reid, CEO
of Ibis
Technology in
Danvers,
announced
another $7m
order from SUMCO
of Japan for its
i2000 oxygen
implanter for
the production
of
300-millimeter
Silicon-on
Insulator (SOI)
wafers. SUMCO
and Ibis have
also agreed to
the terms for
future orders.
The story is
reported by Mass
High Tech,
10/28/05.
This is further
commercial
validation of
this new
technology for
the production
of faster,
smaller
semi-conductors.
The introduction
of new
technology into
the production
of
semi-conductors
is an extremely
difficult
process. The
members of CEO
Roundtable
congratulate
Wood Reid, our
fellow member,
and his team --
it has been a
very long road! |
|
 |
Vinit Nijhawan has been recognized by Mass High Tech
as a High
Tech
All-Star for
his
contribution
to
encouraging
entrepreneurship
as the
President of
TiE-Boston.
Vinit is a
serial
entrepreneur
who believes
that the
innovation
generated by
entrepreneurs
is vital to
the global
economy and
helping
entrepreneurs
succeed is
the mission
of TiE.
Congratulations
to Vinit. |
|
|
 |
Neal Gordon, Epitome Biosystems in MHT
Epitome
Biosystems
is one of
the local
companies
highlighted
by Mass High
Tech as a
leader in
'biomarker'
technology
for use in
the emerging
area of
personalized
medicine.
Epitome has
licensed its
propriarty "EpiTag"
technology
to EMD
Biosciences,
a subsidiary
of Merck
Pharmaceuticals.
Neal Gordon
is the CEO
of Epitome
Biosystems.
Flagship
Ventures is
a leading
investor.
Epitome also
recently
received a
NIH grant
for $500k. |
|
|
  |
Two CEO Roundtable members are in the same story in
Mass High
Tech.
The front
page story
of the Oct
17 issue on
the "Bird
Flu
Concerns"
mentions
that Mark
Leuchtenberger's
company
Therion
Biologics
and Mike
Settles'
company, TGA
Sciences,
are two
local
companies
that could
become
involved in
the search
for a
vaccine for
the highly
publicized
Avian Flu.
We hope they
get the
contracts --
and that we
never have
to use the
vaccine. |
|
|
 |
Peter Savas, Chairman, Boston Life Sciences, Inc. just
announced
that the
company has
received a
new Special
Protocal
Agreement
(SPA) with
the FDA for
the Phase 3
clinical
trial for
ALTROPANE, a
molecular
imaging
agent. The
SPA will
enable
Boston Life
Sciences to
conclude the
pivotal
Phase 3
trials
faster and
at a lower
cost.
ALTROPANE is
being
developed to
aid in the
differentiation
of
Parkinsonian
Syndrome
tremors and
non-Parkinsonian
tremors.
Peter and
his team
have been
working very
hard to
better
position
BLSI's
programs and
assets for
devloment,
approval and
commercialization.
See
www.bostonlifesciences.com
Peter is a
member of
CEO
Roundtable. |
|
|
 |
Bob Linke, CEO of Genomic Profiling Systems, announced
that the
company has
received
$4.1m in a
grant from
National
Institute of
Allergy and
Infectious
Diseases to
develop a
new screener
for anthrax.
The story
reported in
the Boston
Business
Journal by
Sheri
Qualters
(Aug 25, pg
9) also says
that Genomic
Profiling
Systems is
anticipating
commercialization
of its main
product,
Growth
Direct,
early next
year. Growth
Direct tests
for
microbiological
contamination
in
pharmaceutical
product
manufacturing
processes.
Don Straus
is the
founder and
vice
president of
research for
Genomic
Profiling
Systems.
Congratulations
to Bob and
his team. It
is not easy
to invest
the time and
resources to
develop a
future pipe
line when
focused on
delivery of
a major new
product.
Bob is a
member of
CEO
Roundtable. |
|
|
 |
|
Kirtland Poss, CEO of VisEn Medical, announced the
closing of
an
additional
$4m in
venture
capital
investment.
Kirt said
that the
money will
be used
primarily to
launch
commercial
sales of its
molecular
imaging
technologies.
VisEn has
products
that use
Fluorescent
Molecular
Tomography (FMT)
and optical
probe
technology
to produce
quantifiable
molecular
maps of
disease
activities
deep within
the body.
Researchers
and doctors
will be able
to see the
impact of
various
therapies/drugs
directly on
the disease
at the
molecular
level deep
within the
body.
See
www.visenmedical.com
Flagship
Ventures led
this round
of funding
for VisEn.
Congratulations
to Kirt and
his team.
Reaching
commercialization
is a real
achievement.
Kirt is a
member of
one of the
CEO
Roundtables
for biotech
companies. |
|
|
 |
|
Michael Bonny is
featured in the
'Executive
Profile'
section. This
long profile
highlights
Mike's success
in leading
Cubist
Pharmaceuticals
into
commercialization
of its lead
drug, Cubicin.
Mike has led the
company through
some very
difficult
regulatory and
market obstacles
to the $100 m
sales level.
(Boston Business
Journal, Aug
19-25, pg 3) See
www.cubist.com |
|
 |
|
Michael Dempsey and
his company,
Radianse, are
included a BBJ
story on the
fast growth of
the RFID market.
In a special
focus section on
growing
technology
sectors, Brian
Cook reports
that RFID (radio
frequency
identification)
markets are
realizing the
long predicted
growth stage and
Radianse is a
leading example
of a company
experiencing
fast growth .
Radianse
specializes in
the application
of its
proprietary
technology in
hospitals.
(Boston Business
Journal, Aug
19-25, pg 35)
See
www.radianse.com |
|
 |
Richie Faubert,
CEO, AmberWave
Systems in
Salem, NH
announced that
his company is
suing Intel Corp
for patent
infringements.
AmberWave owns
many patents
from its
development work
on semiconductor
technology,
especially in
the area of
'strained
silicon'
manufacturing
techniques.
AmberWave has
been developing
ten years of
research from
AT&T Bell Labs
and MIT to
improve the
quality and
efficiency of
semiconductors.
The story is
reported by
Rashmie Kalke on
the front page
of the BIZ
section of The
Eagle-Tribune,
July 19, 2005.
Richie is a
member of CEO
Roundtable. |
|
 |
Mercia Tapping,
founder and CEO
of
AllergyBuyersClub.com
is listed as #12
on Boston
Business
Journal's list
of Largest
Minority/women
Owned Businesses
in the July 1
issue, pg. 22.
(#1 is Fidelity
Investments)
Mercia has
received many
national and
regional awards
in the past year
for the success
of her company
and her
leadership as an
entrepreneur.
See our web site
for past
reports:
www.ceo-roundtables.com.
Mercia joined
CEO Roundtable
when
AllergyBuyersClub.com
was a new
start-up
operating from
her home. The
company has
expanded and
moved several
times and all of
Mercia's peers
celebrate her
success. |
|
 |
Don Webber, CEO of
Mitralign, is
pictured on the
front page of
The
Eagle-Tribune's
BIZ section
(June 28). The
story by Dave
Price reports
that Mitralign
is developing an
alternative
method to
traditional
open-heart
surgery to
repair leaky
mitral valves.
The company,
located in
Salem, NH,
recently closed
an additional
$10 m in funding
led by Oxford
Bioscience
Partners of
Boston.
See
www.mitralign.com
Congratulations
to Don and his
team and good
luck as they
race to get the
new products to
market.
Don is member of
CEO Roundtable. |
|
 |
|
June 2005 Charles
(Chuck)
Sherwood, CEO,
Anika
Therapeutics, is
profiled in the
Boston Business
Journal in the
Corporate Album
section (June
24, pg 18).
Chuck has a
doctorate in
polymer science
from U Mass-
Amherst. He
joined Anika as
VP of R&D in
2000 and became
President and
COO in 2001 and
then CEO in
2002. He led
Anika through
clinical trials
to
commercialization
and
profitability.
Anika
Therapeutics is
a public company
(ANIK, NASDAQ)
with $26 m in
revenue in 2004.
It's focus is
therapeutic uses
of hyaluronic
acid, a
naturally
occurring
biocompatible
polymer found
throughout the
body. For
example one of
its product's,
OrthoVisc, is
used in the
treatment of
osteoarthritis.
See
www.anikatherapeutics.com.
BBJ recently
ranked Anika as
#7 in its list
of most
successful
Boston area
companies.
Chuck Sherwood
is a member of
CEO Roundtable. |
|
|
|
|
June 2005 The
current issue of
Boston Business
Journal (June
17) reports on
its front page
that Therion
Biologics has
closed on an
additional $30m
in funding. The
story by Mark
Hollmer includes
a photo of Mark
Leuchtemberger,
CEO of Therion.
The company will
use this
additional
funding to
complete a
critical late
stage clinical
trial and
building a
manufacturing
plant in
Cambridge.
Therion is
completing Phase
III human
clinical trials
of Panvac-VF, a
vaccine for the
treatment of
pancreatic
cancer in
patients for
whom
chemotherapy has
failed. Therion
has raised a
total of $140m.
Congratulations
to Mark and his
team as they
near the finish
line in their
efforts.
Mark
Leuchtenberger
is a member of
CEO Roundtable. |
|
 |
|
June 2005 Kees
Been is the new
CEO for EnVivo
Pharmaceuticals
in Watertown,
MA.
EnVivo is
focused on
central nervous
system disorders
like
Alzheimer's,
Parkinson's and
Huntington's
disease. The
company is
largely funded
by Fidelity
Bioscience.
See
www.envivopharma.com
Congratulations
to Kees on his
new position.
Kees Been is a
member of CEO
Roundtable. |
|
 |
|
June 2005 Nancy
Briefs, the
President and
CEO of Percardia,
Inc., has been
elected Chairman
of The Medical
Device
Manufacturers
Association (MDMA)
for a two year
term. As the
Chair of MDMA,
Nancy will be
advocating for
the
entrepreneurial
companies that
bring their
passion and
commitment to
improving health
care with new
technologies.
Percadia is
developing new
heart health and
therapy
technologies.
See
www.percardia.com
Congratulations
to Nancy on this
important new
responsibility
and opportunity
to make a
difference on a
national level.
Nancy is a
member of CEO
Roundtable. |
|
 |
|
May 2005
The Sunday
Boston Globe's
"Globe Magazine"
(May 29, pgs
36-37) has a
wonderful,
colorful story
on Mary Boone
Wellington and
her company,
LightBlocks.
Mary is an
artist who
invented and
patented a
process for
making luminous
plastic
materials that
are used by top
architects in a
variety of
applications and
a variety of
types of
buildings. The
Globe emphasizes
that Mary made a
business
decision to be
both a
commercial
manufacturer and
a creative
artist. The
Museum of Modern
Art in NYC
carries some of
Mary's tableware
creations.
See
www.lightblocks.com
Congratulations
to Mary and her
team for this
recognition of
their capacity
to succeed in
business while
remaining true
to their
artistic vision.
Mary is a member
of CEO
Roundtable. |
|
|
The Sunday Boston
Globe's "Globe Magazine"
(May 29, pgs 36-37) has
a wonderful, colorful
story on Mary Boone
Wellington and her
company, LightBlocks.
Mary is an artist who
invented and patented a
process for making
luminous plastic
materials that are used
by top architects in a
variety of applications
and a variety of types
of buildings. The Globe
emphasizes that Mary
made a business decision
to be both a commercial
manufacturer and a
creative artist. The
Museum of Modern Art in
NYC carries some of
Mary's tableware
creations.
See
www.lightblocks.com
Congratulations to Mary
and her team for this
recognition of their
capacity to succeed in
business while remaining
true to their artistic
vision.
Mary is a member of CEO
Roundtable.
|
|
May 2005 Charles
(Chuck)
Sherwood's
company, Anika
Therapeutics, is
#7 on the
"Boston Globe
100" list as
reported today.
This ranking is
based on a
composite score
of several
factors. Anika
increased
revenues 71.8%
and profits
687.5% producing
a return
on equity of
46.3%. In a
special Globe
100 section the
paper discussed
the importance
of perseverance
in Anika
achieving this
success -- and
Chuck's fellow
CEO Roundtable
members will
attest to this!
It has been a
long hard road.
The market has
rewarded this
effort.
Congratulations
to Chuck and his
great team.
Chuck is a
member of one of
the CEO
Roundtables for
biotech/pharma
companies |
|
|
|
|
May 2005 Mercia
Tapping, Founder
and Chairman,
AllergyBuyersClub.com,
is featured in
this week's
Boston Business
Journal in the
Growth Tools
section (pg 40 &
41). Sean
McFadden of the
BBJ wrote the
report.
In the article
Mercia gives
credit to CEO
Roundtable
members for
helping her get
through the long
dark tunnel of
start-up boot
strapping and
the pains of
rapid growth.
She is now
profitable and
has passed the
$10m milestone.
Two members of
CEO Roundtable
now serve on her
board of
advisors and she
hired another
member to run
her operations.
CEO Roundtable
gave her the
confidence to
reject the
advice of VCs
and stay with
her original
vision of a
company built
around community
and product
evaluations.
Mercia Tapping
is a member of
the CEO
Roundtable for
high tech
companies. We
are very proud
of Mercia's
success. |
|
 |
|
May 2005 Scott
Gillis and his
company, Nucryst
Pharmaceuticals,
in Wakefield, MA
are on the front
page of the
today's Boston
Globe Business
Section (pg.
F10) The
headline is,
"Worth more than
its weight in
silver for
burns". The long
article reports
that Nucryst has
received FDA
approval to
market a new
form of its
Acticoat
treatment for
burns. Silver
particles are
very good at
killing bacteria
and protecting
the body from
infection as the
burn heals.
The
development of
nanosized
particles
increased the
effectiveness of
the treatment.
The new version
is a foam of
nanoparticles of
silver that has
advantages over
the current
dressing because
it will adhere
better to hard
to reach areas
and penetrate
the skin deeper
to kill bacteria
while the burn
heals. Nucryst
markets Acticoat
through Smith &
Nephew to
hospitals and
burn units.
Congratulations
to Scott and his
team. They have
successfully
taken
nanotechnology
from the lab to
the market.
Scott Gillis is
a member of one
of the CEO
Roundtables for
biotech
companies. We
are proud to
have Scott in
the peer group. |
|
 |
|
April 2005 Kedar
Gupta, founder
of GT Equipment
Technologies,
will receive an
award in
Washington, D.
C. tomorrow,
April 14, as the
"Small Business
Environmental
Exporter of the
Year" from the
Export-Import
Bank.
GT Equipment
manufactures
equipment to
produce solar
wafers, cells
and panels. In
2004 it sold a
large turnkey
wafer production
line to Taiwan.
The EX-Im Bank
provided the
financing
guarantee that
GT Equipment
needed to fill
the order. Wells
Fargo provided
the working
capital.
Congratulations
to Kedar and his
team.
Kedar is a
member of the
CEO Roundtable
in New
Hampshire. |
|
|
|
|
March 2005
Mark
Leuchtenberger's
company, Therion
Biologics, is
featured on the
front page of
this week's
"Boston Business
Journal", March
18-24, in an
article by Mark
Hollmer. Therion
has its cancer
vaccine, Panvac-VF,
in Phase III
human clinical
trials. The
vaccine's target
is pancreatic
cancer and it is
intended to help
the patient's
own immune
system fight the
disease.
You can read
more about the
research on
cancer vaccines
in an article
published in
"FDA Consumer",
September-October
2004. Therion's
work is
highlighted in
this article.
Congratulations
to Mark and his
outstanding team
on leading the
way in this very
promising
approach to
cancer therapy.
Mark is a member
of CEO
Roundtable. |
|
|
|
|
March 2005
Mary Boone
Wellington,
owner of MB
Wellington
Studios, is
featured in the
Spring 2005
issue of
Business Week
Small Biz. Many
of you have met
Mary at the
retreats and
special seminars
and you know her
as the artist
who invented a
new material and
built a
manufacturing
business in
order to realize
her artistic
vision. You can
read the text of
the article
online ...
but you should
see the photo
layout in the
magazine!
Mary is a member
of the CEO
Roundtable in
New Hampshire. |
|
|
|
|
March 2005
Kedar Gupta's
company, GT
Equipment
Technologies of
Merrimack, NH
was featured in
a long story
Manchester
"Union Leader"
last Sunday. The
newspaper
reported the
substantial
increase in
sales that GTi
is experiencing
in its solar
power product
lines as fuel
costs continue
to increase.
Kedar reports
that GTi has a
backlog of $40m
for its $700k
systems and more
on the way. Many
of GTi's
customers are in
Asia and Europe.
GTi is planning
to increase
hiring.
This success
story was picked
up by NECN cable
news and WNDS
television.
Congratulations
to Kedar and his
team!
Kedar Gupta is a
member of the
New Hampshire
CEO Roundtable. |
|
|
|
|
February, 2005
The
Eagle-Tribune
(Feb 10) reports
that Mike
Dempsey's
company,
Radianse Inc.,
has redefined
the market
paradigm for
powerful RFID
trackers.
It has started
to deliver $10
RFID tags that
transmit to a
receiver.
This is new
price point for
this type of
technology.
Radianse focuses
on the hospital
market and its
new tags are
disposable.
They can be used
to economically
track patients
within a
hospital, making
sure that the
right patient is
in the right
place receiving
the right
treatment.
This system has
major
implications for
the quality and
cost of
treatment in
hospitals.
Previous
versions of
active RFID tags
cost much more
and are used
primarily to
track capital
equipment.
Mike is a member
of the high tech
CEO Roundtable. |
|
|
|
|
January 2005
Scott Gillis,
CEO of Nucryst
Pharmaceuticals,
announced that
Forbes has named
"Acticoat" one
of the "Top Ten
Nanotech
Products of
2004".
Acticoat is a
nanotech product
used in the
treatment of
serious burns
and chronic
wounds. Nucryst
developed
nanosized silver
particles to
increase the
surface area to
increase the
effectivness of
the bacteria
killing
properties of
the silver.
Acticote is used
as an effective
wound dressing
in over 120
major burn
hospitals in
North America.
The product is
distributed by
Smith & Nephew.
Congratulations
to Scott and his
team -- and good
luck on the new
nanotech
products in the
pipeline.
Scott is member
of one of the
CEO Roundtable
for biotech
companies. |
|
 |
|
January 2005
Marc Beer, CEO
of ViaCell,
completed the
IPO and is
ringing the bell
today!
We are looking
forward to
welcoming Marc
back from the 'roadshow'
and having him
share his
insights with us
-- and to
helping him
transition into
the next stage,
being the CEO of
a public
company. The fun
has just
started.
Congratulations
to Marc and his
team. See the
details in the
attached. |
|
|
|
|
January 2005
Vinit Nijhawan
is profiled in
Mass High Tech
(Jan 17) as a
"Mover &
Innovator" in
the New England
high tech
industry. This
is a very good
profile of
Vinit's career
and achievement
as a 'serial
entrepreneur'.
He is currently
devoting
considerable
time to being
the President of
TiE-Boston, the
group that works
so hard to
promote
entrepreneurship
and growth in
New England.
Congratulations
to Vinit! |
|
 |
|
January 2005
Ellen Richstone
accepted the
offer to become
the new CFO of
Sonus Networks,
a public
company. This
will be a very
challenging
assignment for
Ellen. We will
miss her
participation in
the Roundtable
and we know that
Sonus is getting
a very good,
tough, CFO.
Congratulations
to Ellen. |
|
 |
|
January 2005
LifeSciencesWorld
reported that
Safi Bahcall,
CEO of Synta
Pharmaceuticals,
announced
closing on an
additional $80
million in its
fourth round of
private
financing
since 2002.
Synta has now
raised $200
million.
Synta has a
pipeline of
small-molecule
drugs in
clinical trials.
See
www.syntapharma.com.
Congratulations
to Safi and his
outstanding
team. Safi is
member of one of
the CEO
Roundtables for
biotech
companies in the
Boston area. |
|
|
